Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis
BRISBANE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced an upcoming podium presentation of findings from its Phase 1 study of PCRX-201 (enekinragene inzadenovec), a locally administered gene therapy candidate for osteoarthritis of the knee. The data will be presented at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans on May 15. The presentation will highlight how preexisting and treatment-induced neutralizing antibodies (NAbs) impact the therapy's efficacy, safety, and redosing potential.
Presentation Title: Understanding the Clinical Immunogenicity of Locally Injected HCAd Vector Provides Insight into Optimizing Dosing Strategy
Presented By: MiJeong Kim, PhD, Senior Director of Translational Sciences at Pacira BioSciences
Date and Time: Thursday, May 15 from 2:15–2:30 PM CT, during the 'Immunogenicity/NAb Titers' oral session at ASGCT 2025
Pacira will also host a symposium on HCAd for common diseases, like osteoarthritis.
Symposium Title: High-Capacity Adenoviral Vectors: Advancing Gene Therapy Beyond AAV to Deliver Cost-Effective Therapies for Common Diseases
Speakers:
Date and Time: Friday, May 16 from 12:15–1:15 PM CT
About PCRX-201 (enekinragene inzadenovec)
PCRX-201 (enekinragene inzadenovec) features an innovative design based on the company's proprietary high-capacity adenovirus vector platform. It is currently being studied in the fundamental, underlying chronic inflammatory processes that contribute to 'wear and tear' over time in osteoarthritis of the knee, a condition that affects more than 14 million individuals in the U.S. today.
In November 2024, Pacira reported promising data from a large Phase 1 study in which PCRX-201 provided sustained improvements in knee pain, stiffness, and function through two years following local administration, with a well-tolerated safety profile. PCRX-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and Advanced Therapy Medicinal Products (ATMP) designation from the European Medicines Agency. PCRX-201 is the first gene therapy to achieve these clinical results and earn these regulatory designations in osteoarthritis of the knee – a testament to its promise and potential.
Given the promising Phase 1 results, dosing is underway in a Phase 2 study of PCRX-201 ( the ASCEND study ) for the treatment of knee osteoarthritis. To learn more about PCRX-201 and the company's clinical development program, please visit the investor events section of the company's investor website.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®°, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Investor Contact: Susan Mesco, (973) 451-4030 [email protected] Media Contact: Sara Marino, (973) 370-5430 [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Upcoming Stock Splits This Week (June 16 to June 20)
These are the upcoming stock splits for the week of June 16 to June 20, based on TipRanks' Stock Splits Calendar. A stock split occurs when a company issues additional shares to existing investors, increasing the total share count without changing its overall market value. The result is a lower price per share, making the stock appear more affordable to everyday investors. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter On the flip side, a reverse stock split shrinks the share count by combining existing shares, driving the price per share higher while keeping the total valuation intact. Companies often use this move to stay in compliance with stock exchange rules, particularly when their share price is hovering near delisting thresholds like Nasdaq's minimum requirement. Whether to attract investor attention or to meet listing standards, these maneuvers can offer important clues about a company's current priorities and future strategy. Let's take a look at the upcoming stock splits for the week. Jianzhi Education Technology Group (JZ) – Beijing‑based Jianzhi is a digital education provider offering online learning platforms and professional development content to higher education institutions and individuals across China. On June 12, the company announced an upcoming 1‑for‑10 reverse ADS split to boost its ADS trading price and maintain Nasdaq listing compliance. The split is scheduled to be effective at the start of trading on June 16. GlycoMimetics (GLYC) – U.S.-based GlycoMimetics is a clinical-stage biotech company developing treatments for sickle cell disease and cancer by targeting cell adhesion. On June 5, the company announced a 1-for-100 reverse stock split to support its planned merger with Crescent Biopharma. The split will take effect June 16, with shares trading under the new ticker CBIO as the combined company moves forward. Neo-Concept International Group Holdings (NCI) – Neo-Concept is a Hong Kong-headquartered apparel supplier and importer serving global e-commerce platforms. Following shareholder approval at its May 9 meeting, the company is rolling out a 1-for-5 reverse share consolidation. The adjustment takes place June 16. Shuttle Pharmaceuticals (SHPH) – Shuttle Pharmaceuticals is advancing a pipeline of radiation-sensitizing drugs aimed at improving cancer outcomes. On June 12, it unveiled a 1-for-25 reverse stock split to bring its share price back in line with Nasdaq's minimum bid requirement. The split becomes effective June 16, with SHPH shares trading on a split-adjusted basis that morning. Jeffs' Brands (JFBR) – Jeffs' Brands operates data-driven e-commerce brands across major online marketplaces, including Amazon. After securing shareholder approval, the company announced on June 12 a 1-for-17 reverse stock split aimed at maintaining its Nasdaq listing. The change goes live June 16. Security Matters (SMX) – Dublin-based Security Matters offers advanced digital tracking and authentication solutions for supply chains and product integrity. The company is implementing a 4.1-for-1 reverse stock split, which was approved earlier this spring and formally announced on June 12. The split is scheduled to take effect June 16. Glucotrack (GCTK) – Glucotrack is a med-tech innovator developing non-invasive glucose monitoring solutions for diabetes management. To meet Nasdaq compliance standards, the company announced a 1-for-60 reverse stock split on June 12, following prior shareholder approval at its May 22 annual meeting. The split becomes effective June 16. Regencell Bioscience Holdings (RGC) – Hong Kong–based Regencell is on a mission to treat neurocognitive disorders like ADHD and autism using traditional Chinese medicine. On June 2, the company unveiled a 38-for-1 forward stock split to boost liquidity and attract retail interest. Shareholders of record as of June 12 received their additional shares on June 13, and RGC began trading on a split-adjusted basis on June 16. Sensei Biotherapeutics (SNSE) – Sensei is a clinical-stage biotech based in Boston, developing next-gen immunotherapies to take on cancer. On June 13, the company announced a 1-for-20 reverse stock split in an effort to meet Nasdaq's minimum price threshold and maintain its listing. The split takes effect on June 16, with adjusted trading kicking off on June 17. RAPT Therapeutics (RAPT) – RAPT is advancing innovative therapies targeting inflammatory and autoimmune diseases. On June 13, the company rolled out a 1-for-8 reverse stock split aimed at reshaping its capital structure. The move becomes official on June 16, with split-adjusted shares starting to trade on June 17. FibroGen (FGEN) – FibroGen is a biotech company focused on fibrosis and other serious diseases. On June 12, it announced a 1-for-25 reverse stock split designed to help the stock climb back above the Nasdaq's minimum bid requirement. The split becomes effective on June 16, with trading on a split-adjusted basis beginning June 17. Interactive Brokers Group (IBKR) – A powerhouse in online trading, Interactive Brokers is known for serving active investors with low-cost, high-tech tools. On April 15, the company declared a 4-for-1 forward stock split to make shares more accessible to a broader investor base. Shareholders of record on June 16 received the extra shares on June 17, and IBKR stock began trading at the new price on June 18. TipRanks Stock Splits Calendar.
Yahoo
3 hours ago
- Yahoo
Veteran analyst sends surprising message on stocks, bonds, and gold
Veteran analyst sends surprising message on stocks, bonds, and gold originally appeared on TheStreet. The stock market rally has been impressive. Since President Donald Trump paused most reciprocal tariffs on April 9, only days after announcing them, stocks have soared. The S&P 500 has gained about 20%, while the tech-stock heavy Nasdaq Composite is up 27%. Those returns in such a short span significantly outpace the average 10% annual return for stocks since 1928. Stocks haven't been the only winner. Gold has also notched impressive returns this year. The yellow metal has rallied 30% in 2025 as investors have sought to insulate risk amid growing economic concerns surrounding debt and the impact of tariffs on one big disappointment this year: Treasury bonds. They've tumbled, sending bond yields soaring, as global investors have soured on financing America's insatiable appetite for spending. The market action has captured the attention of many, including veteran commodities and futures analyst Carley Garner. Garner has been professionally navigating these markets for 20 years, and her track record includes accurately predicting the stock rally in 2023 and last year's decline in oil prices. Garner updated her outlook on stocks, gold, and bonds, and her takeaway may surprise you. Stocks' rally since the lows in early April likely surprised many, given significant economic risks remain. While inflation has retreated below 3% from over 8% in 2022, price increases over the past years have cash-strapped consumers, causing them to shift spending from discretionary purchases to problem has been compounded by an uptick in unemployment, which has increased to 4.2% from 3.4% in 2023, partly due to higher interest rates designed to crimp inflation. According to Challenger, Gray, & Christmas, U.S. companies have laid off 696,309 workers this year through May, up 80% from one year ago. The situation isn't likely to get much better for workers. While Trump paused many reciprocal tariffs in April, key tariffs remain, including a 25% tariff on Canada and Mexico and autos, a 10% tariff on all imports, and 30% tariff on China (total tariffs on China, including those put in place during President Trump's first term exceed 50%). The remaining tariffs, and potential for more after the 90-day pause expires, could fuel inflation later this year, particularly in retail, which sources everything from clothing to electronics from overseas. The risk of inflation alongside job losses suggests America could go headlong into a period of stagflation or recession. Despite those risks, the S&P 500 and Nasdaq Composite have notched remarkable gains. Investors who quickly sold amid tariff announcements earlier this year have been left behind, and as a result, they're buying every dip to regain their exposure. One major exception? Warren Buffett. The Oracle of Omaha has increased Berkshire Hathaway's cash position, choosing to collect guaranteed fixed income from T-bills rather than leap back into the stock market amid the uncertainty. Exiting the first quarter, Warren Buffett's cash stockpile eclipsed $347 billion, a record, and more than double the levels exiting 2023. The rallies in stocks and gold may continue, but like Buffett, Carley Garner doesn't see the risk-to-reward as overly compelling in stocks. She's also become bearish on gold relative to bonds, given that gold has moved significantly higher and, unlike bonds, doesn't pay dividends. "While I believe the S&P 500 can easily reach 6300 to 6400, the downside risk might be outsized relative to the potential reward," wrote Garner on TheStreet Pro. "Since 1928, the S&P 500 has returned an average annual rate of 10%; however, in recent years, the average return has been abnormally high, at approximately 14%. There is a good chance that, like the dot-com era, we have pulled forward gains and could be on the verge of a 'returnless' market in the coming years." Garner points to a key measure favored by Warren Buffett regarding stock market valuation as evidence that stocks are over their skis. More Experts: Fed official sends strong message about interest-rate cuts Billionaire fund manager sends surprising message on trade deficit Hedge-fund manager sees U.S. becoming Greece "The Warren Buffett Indicator measures the total stock market value vs. the GDP," wrote Garner. "Since 1950, the stock market has only been this overstretched a few other times. Not surprisingly, the dot-com bubble was one of those times. Historically, this indicator has not been the time to hit the gas on risk assets. It has been the opposite." The arguable overvaluation of stocks could mean the risk of a reckoning is high enough to concentrate on other assets. However, gold may not be the best bet, given it's already made a big move higher. Instead, it's Treasury bonds that Garner believes offer the best chance for upside. "There is only one [of these assets] near a two-decade low in valuation: Treasuries," writes Garner. "Except for some forms of real estate, it is the only asset that yields an attractive income stream. Lastly, Treasuries are the least risky asset class in the world but the market is treating the securities as anything but." Garner points out that people were flocking to own bonds with paltry yields only five years ago. Now, they're shunning yields near 4.5%. Many are hesitant to own bonds despite the high yields, fearing that bonds will continue to drop, sending yields even higher, as the U.S. debt load rises. While it's true that lower bond values could mean short-term losses, Garner views the risk of a U.S. default as unlikely, suggesting that those holding Treasuries to maturity will be fine, and pocket healthy income along the way. "Historically, there have been two other instances in history when stocks were as overvalued as they are now relative to bonds. Or, alternatively, bonds were this undervalued relative to stocks," wrote Garner. "Such opportunities have only arisen once every two decades, and they have proven to be significant inflection points in both stocks (the beginning of prolonged underperformance) and bonds (the start of a period of capital gains to enhance interest earned). This metric has been similarly favoring bonds since the initial collapse in 2023, so instant satisfaction shouldn't be expected, but patience will likely pay off."Veteran analyst sends surprising message on stocks, bonds, and gold first appeared on TheStreet on Jun 15, 2025 This story was originally reported by TheStreet on Jun 15, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Duolingo Stock Is Overvalued, According to Wall Street. Time to Sell?
Duolingo stock has surged to levels that do not make sense for some investors. The underlying business is performing extraordinarily well, and management isn't resting on its laurels. 10 stocks we like better than Duolingo › After jumping a hefty 43% in 2024, shares of language-learning app Duolingo (NASDAQ: DUOL) are up another 47% so far in 2025. And according to select Wall Street analysts, the stock has simply climbed too far, too quickly. Stock research platform TipRanks is currently tracking 15 analysts who cover Duolingo stock. Of these analysts, none recommend selling the stock, but their average price target is $476 per share, slightly below where Duolingo is trading as of this writing. In other words, Duolingo stock trades above what these professionals believe it's worth. It's obviously time to sell, right? Well, it's more complicated than that. Most Wall Street price targets only take into account the next 12 to 18 months. But for those who want to consistently do well investing in stocks, a long-term view is beneficial. Investors who hold stocks for five years or more tend to outperform their less patient counterparts. But the buy-and-hold philosophy can't be used indiscriminately. To the contrary, the underlying business still needs to do well during the holding period -- buying and holding businesses with declining fundamentals is still a losing proposition. Therefore, that's the first thing to consider with Duolingo: Is this business poised to do well over the next five years? Duolingo is known for its language-learning courses, and that business is absolutely booming. Nearly 47 million people used the platform every single day during the first quarter of 2025, and 10 million people pay for a subscription that offers extra perks, a whopping 40% increase from the prior-year period. Duolingo's management attributes its success to a variety of factors, but here are two big ones. First, the company does a lot of A/B testing, constantly making changes based on what's working with its users. Second, it also incorporates a lot of game-like elements into the learning process, keeping users motivated and engaged. Now, Duolingo is taking its language expertise and broadening its focus to other verticals, such as math, music, chess, and more. There's no limit to what the company can do when it comes to launching courses and programs, which greatly increase its market opportunity. For what it's worth, companies that can easily expand their market opportunity with related products and services often do well over the long term. Revenue growth is important for creating shareholder value, and it's easier to grow the top line when the opportunity is getting bigger. Since the start of 2022, Duolingo has averaged over 40% quarterly revenue growth, meaning revenue is doubling about every two years. That's extraordinary. Now, generative artificial intelligence (AI) is helping Duolingo develop new products faster than ever. It launched nearly 150 new language courses in Q1 alone. For some investors, this is a good thing -- the company can expand and grow even more quickly. For others, however, this technology presents a risk to Duolingo. Generative AI could also make it easier for other companies to offer competing services. This two-sided risk should be acknowledged, even as Duolingo's business is thriving. I believe it's safe to say that, trading at nearly 30 times its sales, Duolingo stock doesn't look like a bargain at the moment. The chart below shows that a large portion of the stock's gains this year are due to an expanding valuation multiple, which should always give potential new investors pause. The reality is that as Duolingo gets bigger, its growth will likely slow. But even if you assume it sustains a 40% growth rate, the company would generate $4.0 billion in annual revenue by 2029. With a current market capitalization of $21.9 billion, Duolingo still trades at 5.5 times that 2029 sales forecast. That premium leaves investors with the difficult job of weighing a growing business with sound fundamentals and a large market opportunity against a share price that's increasingly hard to justify. None of this is to say existing Duolingo shareholders should be selling out of their positions. Personally, I'm waiting on the sidelines for a price that makes sense to me before buying the stock. Those who decide to buy now are best served by maintaining a long-term perspective. Before you buy stock in Duolingo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Duolingo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor's total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Jon Quast has no position in any of the stocks mentioned. The Motley Fool recommends Duolingo. The Motley Fool has a disclosure policy. Duolingo Stock Is Overvalued, According to Wall Street. Time to Sell? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
